ID: ALA234371

Max Phase: Preclinical

Molecular Formula: C34H21Cl3N2O5

Molecular Weight: 643.91

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)c1cccc(NC(=O)c2ccc(OCc3c(-c4c(Cl)cccc4Cl)noc3-c3ccc4ccccc4c3)cc2Cl)c1

Standard InChI:  InChI=1S/C34H21Cl3N2O5/c35-27-9-4-10-28(36)30(27)31-26(32(44-39-31)21-12-11-19-5-1-2-6-20(19)15-21)18-43-24-13-14-25(29(37)17-24)33(40)38-23-8-3-7-22(16-23)34(41)42/h1-17H,18H2,(H,38,40)(H,41,42)

Standard InChI Key:  LFODZVYWAHZURL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 643.91

Molecular Weight (Monoisotopic): 642.0516

AlogP: 9.65

#Rotatable Bonds: 8

Polar Surface Area: 101.66

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.92

CX Basic pKa:

CX LogP: 9.06

CX LogD: 5.85

Aromatic Rings: 6

Heavy Atoms: 44

QED Weighted: 0.17

Np Likeness Score: -1.05

References

1. Kainuma M, Makishima M, Hashimoto Y, Miyachi H..  (2007)  Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.,  15  (7): [PMID:17292610] [10.1016/j.bmc.2007.01.046]

2. Xu Y..  (2016)  Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases.,  59  (14): [PMID:26878262] [10.1021/acs.jmedchem.5b00342]

Source

Source(1):

• Scientific Literature